About MITRO

Company Profile

Management Team

Evolution

News

Mitro and North Biotechnology Collaborate to Build World-Leading Integrated Radiopharmaceutical Industry Chain Platform

2025-08-07 15:06

July 2025, MITRO Biotech Co., Ltd. (hereinafter referred to as "Mitro") announced a formal strategic cooperation agreement with Beijing North Biotechnology Research Institute Co., Ltd. (hereinafter referred to as "North Biotechnology"). This powerful alliance, anchored by the vision "Nuclear Power for a Healthy China," aims to jointly create a world-leading integrated innovation platform for radiopharmaceuticals spanning the entire industry chain. The collaboration will accelerate breakthroughs in critical "bottleneck" technologies for α and β radionuclide targeted diagnosis and treatment, driving China's nuclear medicine industry towards greater self-sufficiency and global expansion.

The cooperation focuses on building a comprehensive industry chain system covering "Technology Introduction/Development – Clinical Translation – Scale Manufacturing – Global Market." A "Frontier Radionuclide Drugs and Novel Isotope Innovation Laboratory" will be established under North Biotechnology's banner, enabling the leap from technology import to global export. North Biotechnology and its affiliated entities, Hunan Zhonghe Cancer Hospital and Hunan Zhonghe Medical Co., Ltd., will be responsible for localized scale manufacturing, multi-center clinical research, and domestic/international market development. Together with Mitro, they will form a synergistic, "four-in-one" strategic system integrating "Global Resource Consolidation, Localized Smart Manufacturing Upgrade, and Clinical-Market Translation."

This strategic partnership between Mitro and North Biotechnology marks a significant step forward in Mitro's commitment to advancing innovation within China's radiopharmaceutical industry and achieving autonomy in critical technological domains. Leveraging their respective strengths, the partners will accelerate the R&D and commercialization of innovative nuclear medicine products, bringing benefits to more cancer patients worldwide and jointly pioneering a new era in precision nuclear medicine diagnostics and therapeutics.

About Northern Biotechnology ：

Beijing North Biotechnology Research Institute Co., Ltd. (hereinafter referred to as "North Biotechnology") was established in 1985 and is a wholly-owned subsidiary of China National Nuclear Corporation's CNNC Health Investment Co., Ltd. The company is committed to providing high-quality products and services for human health, and upholds the mission of focusing on in vitro diagnostics and serving human health. With 40 years of deep cultivation in the field of in vitro diagnostics (IVD), it is one of the earliest institutions in China engaged in the research and development, production, sales, and testing of immunological diagnostic reagents, and is a national high-tech enterprise.

About Mitro ：

Established in 2012, MITRO Biotech Co., Ltd. focuses on providing professional and efficient CRO and CDMO services of radiolabeling and molecular imaging to the global pharmaceutical and biopharmaceutical industries. With Radiolabeling and Molecular Imaging technology, MITRO provides outsourcing technical services such as drug screening, biodistribution, PK study and PD evaluation for pharmaceutical enterprises and research institutes at home and abroad. It also provides one-stop solutions for new drug R&D, including labeling method development, pharmacological studies, non-clinical studies, clinical studies, and registration application. Our business focuses on studies such as oncological, nervous system diseases, autoimmune diseases, cardiovascular and cerebrovascular diseases, as well as innovative therapies such as immunity, gene therapy, and cell therapy, so as to explore disease mechanisms, developing diagnostic and therapeutic drugs, and evaluate therapeutic effects.